A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness (BLAZE-4)
The purpose of this study is to measure how well monoclonal antibodies work, either alone or in combination, against the virus that causes COVID-19. Study drug(s) will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study.
Trial Summary
Key Requirements
Clinical trials have inclusion and exclusion requirements to determine which individuals qualify for participation. Listed below are key requirements for this clinical trial, but there may be additional requirements to qualify.Participants Must:
Participants must have mild to moderate COVID-19 illness: Fever, cough, sore throat, not feeling well, headache, muscle pain, digestive symptoms, shortness of breath when active, stuffy or runny nose, new loss of smell, chills
Participants must test positive for COVID-19 within three days before starting the study
Participants Must Not:
Participants must not be in the hospital
Participants must not need a machine to help them breathe (ventilator)
Participants must not be pregnant or breastfeeding
Lilly Trial Alerts
You will complete the questionnaire on another website.YesNo